

Financial Tear Sheet

Corporate Profile

Who is Organovo?

- We are a biotechnology company pioneering a unique set of therapeutic and drug profiling capabilities based on our revolutionary ability to 3D bioprint tissues that emulate human biology and disease.
- We are developing *in vivo* liver tissues to treat a range of rare, life-threatening diseases, for which there are few current treatment options other than organ transplantation.
- We are capitalizing on our foundational ability to isolate highly specialized human cells to build robust, functional human tissues by creating a range of novel preclinical *in vitro* disease modeling platforms.
- We are striving to change the face of medicine by enabling translational drug discovery and through clinical development of novel approaches to treating disease.

 [2018 Annual Report](#)  [Investor Presentation](#)

Stock Information

| ONVO (Common Stock) | |
|----------------------------------|--------------------|
| Exchange | NASDAQ (US Dollar) |
| Price | \$1.09 |
| Change (%) | ▼ 0.01 (0.91%) |
| Volume | 478,016 |
| 52 Week Low | \$0.91 |
| Market Cap | \$124,794,284 |
| Rolling EPS | -0.30 |
| PE Ratio | 0 |
| Shares Outstanding | 113,449,349 |
| Data as of 10/17/18 4:00 p.m. ET | |

Primary IR Contact

Steve E. Kunszabo
 VP, Investor Relations & Corporate Communications
Phone: 858-224-1092
Email: skunszabo@organovo.com



Recent Press Releases & Upcoming Events

10/15/18

Organovo to Present New Preclinical Data on 3D Bioprinted Human Liver Tissues for the Treatment of Tyrosinemia I at the Liver Meeting® 2018 (AASLD)

09/26/18

Organovo to Present at 2018 Cell & Gene Meeting on the Mesa

08/14/18

Organovo Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

There are currently no events scheduled.

SEC Filings

| Filing Date | Form |
|-------------|------|
| 08/16/18 | 4 |
| 08/16/18 | 4 |
| 08/16/18 | 4 |
| 08/16/18 | 4 |

Corporate Governance

| | |
|--------------------------------|--|
| Taylor J. Crouch | President & Chief Executive Officer |
| Sharon Collins Presnell, Ph.D. | Chief Scientific Officer, Organovo & President, Samsara |
| Eric Michael David, M.D., J.D. | Chief Strategy Officer and Executive Vice President of Preclinical Development |
| Jennifer Kinsbruner Bush, J.D. | General Counsel, Corporate Secretary and Compliance Officer |
| Susan Daugherty | Senior Vice President, Human Resources |
| Paul Gallant | General Manager |